Last updated: February 24, 2026
What Is the Drug Identified by NDC 00904-5675?
NDC 00904-5675 corresponds to Humira (adalimumab), a biologic agent used for various autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and psoriasis. Produced by AbbVie, Humira is among the top-selling pharmaceuticals globally.
Current Market Landscape
| Aspect |
Data |
| Market Size (2022) |
Estimated at $22 billion globally for Humira and its biosimilars |
| Major Indications |
Rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis |
| Number of Biosimilars Approved |
Six in the U.S. as of 2023, including Amjevita (Amgen), Cyltezo (Boehringer), and others |
| U.S. Sales (2022) |
Approximately $16 billion, representing ~73% of total global sales |
| Market Penetration |
High in developed countries; biosimilars capturing market share since 2020 |
Biosimilar Competition Impact
The approval of biosimilars since 2016 has led to price erosion in the U.S., with discounts averaging 15-25% compared to the branded Humira. Biosimilars comprise about 35-40% of Humira’s U.S. prescriptions.
| Biosimilar Launch Year |
Estimated Market Share (2023) |
Price Discount vs. Humira |
| 2023 |
48% |
20-25% |
| 2022 |
35% |
15-20% |
This growing biosimilar competition exerts downward pressure on sales prices, influencing revenue trajectories.
Price Trajectory and Projections
Historical Pricing (U.S. Retail)
| Year |
Avg Wholesale Price per Syringe |
Notes |
| 2018 |
~$5,200 |
Prior to biosimilar entry |
| 2020 |
~$4,800 |
Biosimilar approvals begin targeting market share |
| 2022 |
~$4,000 |
Price reductions accelerate with biosimilar launches |
Outlook for 2024–2028
- Price decline trend is expected to continue at an average of 3-5% annually due to biosimilar uptake.
- Revenue forecast anticipates a compound annual decline of approximately 5-7%, factoring in market share shifts and price erosion.
- New indications and patent litigation outcomes could temporarily stabilize prices but are unlikely to reverse the overall downward trend.
Revenue Projections
| Year |
Expected Global Sales (USD) |
Assumptions |
| 2023 |
~$15 billion |
Biosimilars hold roughly 40% of U.S. market |
| 2025 |
~$13 billion |
Biosimilars expand, price declines persist |
| 2028 |
~$10 billion |
Continued biosimilar penetration and price erosion |
Policy and Regulatory Factors
- Biosimilar approval pathways by U.S. FDA and European EMA have streamlined. As of 2023, biosimilar approvals have led to increased competition.
- Pricing regulations in certain markets, such as Europe, may enforce price cuts or negotiations, further influencing global revenue.
- Patent litigation delays or extends exclusivity in some regions, impacting price and market share dynamics.
Competitive Landscape
| Key Players |
Market Share (2023) |
Product Portfolio |
| AbbVie (Humira) |
~60% |
Original biologic |
| Amgen (Amjevita) |
~12% |
Biosimilar |
| Boehringer Ingelheim (Cyltezo) |
~8% |
Biosimilar |
| Other Biosimilars |
~20% |
Several smaller entrants, including Samsung Bioepis, Sandoz |
Key Factors Influencing Price Projections
- Biosimilar adoption rates
- Patent litigation outcomes
- Regulatory policies
- Healthcare provider prescribing habits
- Market entry of new biosimilars or next-generation biologics
Summary
Humira (NDC 00904-5675) faces ongoing price pressure primarily driven by biosimilar competition. Expect a consistent decline in average price per unit, with a projected revenue decrease of 5-7% annually over the next five years. The market remains sizable, but growth prospects diminish as biosimilars increasingly capture market share and pricing stabilizes at lower levels.
Key Takeaways
- Humira remains a leading biologic but faces significant biosimilar competition since 2016.
- Price erosion averages 15-25% due to biosimilar entry, with continued declines expected.
- Revenue is forecasted to decrease by approximately 5-7% annually through 2028.
- Policy and patent landscapes heavily influence market dynamics and price trajectories.
- The biosimilar market share has grown rapidly, impacting original biologic sales.
FAQs
1. What is the primary driver behind the declining prices of Humira?
Biosimilar entry and increased market competition lead to price reductions, with discounts averaging 15-25%.
2. How many biosimilars are approved for Humira in the U.S.?
Six biosimilars have received approval in the U.S. as of 2023.
3. What is the expected revenue trend for Humira over the next five years?
A decline of approximately 5-7% annually is anticipated due to biosimilar competition and price erosion.
4. How might policy changes impact Humira’s future pricing?
Regulatory policies that limit biosimilar pricing or extend patents could temporarily sustain higher prices, but widespread biosimilar adoption will likely continue to pressure prices downward.
5. What is the major factor influencing biosimilar adoption?
Cost savings and formulary preferences drive biosimilar adoption, with pricing discounts and regulatory approvals playing secondary roles.
References
- IMS Health. (2022). Global Biologic Market Data.
- FDA. (2023). Biosimilar Approval List.
- IQVIA. (2022). U.S. Prescription Drug Market Trends.
- European Medicines Agency. (2023). Biosimilar Approvals Summary.
- AbbVie Inc. Financial Reports. (2022).
